Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF5DLW)

• Drug Name: Alpha-D-Mannose Drug Info
• Synonyms: alpha-D-Mannose; alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 185698
  ChEBI ID: CHEBI:28729
  CAS Number: CAS 7296-15-3
  TTD Drug ID: DMF5DLW

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface antigen CD2 (CD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siplizumab	DM75RFJ	Lymphoma	2A80-2A86	Phase 2	[2]
Cyclo(1,12)PenIYDTKGKNVLC-OH	DMVDS8B	Discovery agent	N.A.	Investigative	[3]
Pen(Acm)AQFRKEKETFC(Acm)-OH	DM81AWU	Discovery agent	N.A.	Investigative	[3]
Cyclo(1,11)H-ESIYDPGDDIK-OH	DM4A1TF	Discovery agent	N.A.	Investigative	[4]
Cyclo(1,10)H-EIYDPGDDIK-OH	DM5CBQ9	Discovery agent	N.A.	Investigative	[4]
Cyclo(1,10)EIYDPGDDIK	DMFUG05	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[1]
Beta-D-Mannose	DMHIG9K	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting ADAM metallopeptidase 33 (ADAM33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8772478, 5	DMHI6RZ	N. A.	N. A.	Patented	[7]
US8772478, 3	DMN4FRE	N. A.	N. A.	Patented	[7]
US8772478, 1	DM2J8IS	N. A.	N. A.	Patented	[7]
US8772478, 2	DMFJD5L	N. A.	N. A.	Patented	[7]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[9]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[10]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[11]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[12]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[13]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[14]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[15]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[16]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[18]

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[19]
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[20]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[21]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[6]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[1]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[22]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	DMUCJA6	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Alpha-galactosidase A (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegunigalsidase alfa	DMOUW65	Fabry disease	5C56.01	Approved	[24]
Migalastat	DMFIQ2H	Fabry disease	5C56.01	Approved	[25]
AVR-RD-01	DMC1XHK	Fabry disease	5C56.01	Phase 1/2	[26]
ST-920	DMOJIPG	Fabry disease	5C56.01	Phase 1/2	[27]
4D-310	DMNG59Y	Fabry disease	5C56.01	Phase 1/2	[28]
isaralgagene civaparvovec	DM5SSPZ	Fabry disease	5C56.01	Phase 1/2	[29]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[30]
Beta-1-C-Butyl-1-deoxygalactonojirimycin	DMMKDEZ	Discovery agent	N.A.	Investigative	[30]
Beta-1-C-butenyl-1-deoxygalactonojirimycin	DM6GTBC	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting Lactase-phlorizin hydrolase (LCT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]
Nojirimycine Tetrazole	DMYZRTB	Discovery agent	N.A.	Investigative	[6]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[30]
Gluconolactone	DMO071E	Discovery agent	N.A.	Investigative	[6]
ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE	DM0O4A2	Discovery agent	N.A.	Investigative	[6]
Hyacinthacine B3	DMJ9KNU	Discovery agent	N.A.	Investigative	[31]
D-Gluconhydroximo-1,5-Lactam	DM527XP	Discovery agent	N.A.	Investigative	[6]
2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol	DMKP7O0	Discovery agent	N.A.	Investigative	[32]
2-Deoxy-2fluoro-Glucose	DMMC8IG	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[33]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[34]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[35]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[36]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[37]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[38]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[39]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[40]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[41]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[42]

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[1]
Miltefosine	DMND304	Chronic urticaria		Approved	[43]
Clocortolone	DM9ZMQH	Exanthem		Approved	[44]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[45]
Diflorasone	DMI9PRJ	Exanthem		Approved	[46]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[47]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[48]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[49]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[50]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[51]

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[52]
Zanamivir	DMFMBZ4	Influenza	1E30-1E32	Approved	[52]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[53]
UX-001	DMD2O0L	Hereditary inclusion body myositis	4A41.2	Phase 3	[1]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[53]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[54]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[1]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[55]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[56]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[57]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[58]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[59]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[60]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[61]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[62]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[63]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[64]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[65]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[66]

Drug(s) Targeting Membrane-associated lectin type-C (CD209)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[67]
Naproxen	DMZ5RGV	Bursitis		Approved	[68]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[69]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[70]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[71]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[38]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[72]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[38]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[73]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[74]

Drug(s) Targeting Cathepsin D (CTSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID10498202C1	DMXE0F2	Multiple sclerosis	8A40	Clinical trial	[75]
CI-992	DMBHYIJ	Hypertension	BA00-BA04	Terminated	[76]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[77]
PMID8410973C3	DM6J5KY	Discovery agent	N.A.	Investigative	[78]
KNI-10006	DMMISH6	Discovery agent	N.A.	Investigative	[79]
GRL-7234	DMR93MK	Discovery agent	N.A.	Investigative	[80]
S-Methylcysteine	DMAMRKS	Discovery agent	N.A.	Investigative	[1]
Carbocyclic Peptidomimetic	DM87SOX	Discovery agent	N.A.	Investigative	[81]
N-Aminoethylmorpholine	DMWXBYC	Discovery agent	N.A.	Investigative	[1]
1h-Benoximidazole-2-Carboxylic Acid	DMNZAVE	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Lactotransferrin (LTF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Parecoxib	DMIV8CT	N. A.	N. A.	Phase 4	[6]
Talactoferrin	DMV7T64	Diabetic foot ulcer	BD54	Phase 3	[82]
HLF 1-11	DMDFG1O	Bacteremia	1A73	Phase 1/2	[83]
Nimesulide	DMR1NMD	Metastatic colorectal cancer	2B91	Terminated	[84]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Fucose	DM6VH7A	Discovery agent	N.A.	Investigative	[1]
Nitrilotriacetic Acid	DMIOQFU	Discovery agent	N.A.	Investigative	[1]
3h-Indole-5,6-Diol	DMBFCTZ	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Antithrombin-III (ATIII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[38]
Heparin Calcium	DMEVXY6	Coagulation defect	3B10.0	Approved	[38]
Sulodexide	DMNUC42	Tinnitus	MC41	Approved	[85]
Heparin Sodium	DM9KHZL	Coagulation defect	3B10.0	Approved	[86]
Unfractionated heparin	DMCWM03	Thrombosis	DB61-GB90	Phase 3	[87]
Heparin low molecular weight	DMGFULM	Thrombosis	DB61-GB90	Phase 3	[88]
KW-3357	DMP3GI2	Coagulation defect	3B10.0	Phase 3	[89]
O-desulfated heparin	DMJL4A7	Chronic obstructive pulmonary disease	CA22	Phase 2	[90]
M118	DML0I2Z	Acute coronary syndrome	BA41	Phase 2	[91]
PMX-60056	DMWT73D	Coagulation defect	3B10.0	Phase 2	[92]

Drug(s) Targeting Liver carboxylesterase (CES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[1]
PACTIMIBE	DM0NZDT	Arteriosclerosis	BD40	Phase 2/3	[93]
K-604	DMQVN6P	Arteriosclerosis	BD40	Phase 2	[94]
Eldacimibe	DML7WP0	Hyperlipidaemia	5C80	Phase 2	[95]
GR148672X	DM7W6YN	Acute lymphoblastic leukaemia	2A85	Clinical trial	[96]
Avasimibe	DMFG4OM	Peripheral vascular disease	BD4Z	Discontinued in Phase 3	[97]
E-5324	DM562BM	Hyperlipidaemia	5C80	Discontinued in Phase 2	[98]
RP-64477	DMTQ3BS	Hyperlipidaemia	5C80	Discontinued in Phase 2	[99]
CI-976	DMBO28J	Hyperlipidaemia	5C80	Discontinued in Phase 2	[100]
CL-283796	DM7LIDT	Hyperlipidaemia	5C80	Discontinued in Phase 2	[101]

Drug(s) Targeting Influenza Hemagglutinin (Influ HA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arbidol	DMOQK8Z	Virus infection	1A24-1D9Z	Approved	[102]
CR8020	DMQ47U6	Influenza virus infection	1E30-1E32	Phase 2	[103]
RG7745	DMK5PYS	Infectious disease	1A00-CA43.1	Phase 2	[104]
VIS410	DM1G6ME	Influenza A virus infection	1E30	Phase 2	[105]
ND-1.1	DMVQAEK	Influenza virus infection	1E30-1E32	Phase 1	[106]
VGX-3400	DMGMEH7	Influenza A virus H5N1 infection	1E30	Phase 1	[107]
A/Anhui/05	DMGJ7A4	Influenza virus infection	1E30-1E32	Phase 1	[108]
VIR-2482	DM6LQIU	Influenza A virus infection	1E30	Phase 1	[109]
BMY-27709	DMAMYWL	Discovery agent	N.A.	Investigative	[110]
PXVX-0103	DM2P0I4	Discovery agent	N.A.	Investigative	[111]

Drug(s) Targeting Beta-2-glycoprotein 1 (APOH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LJP-1082	DM9WEP5	Hughes syndrome	4A45.Z	Discontinued in Phase 1	[112]

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[9]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[38]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[113]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[114]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[115]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[116]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[117]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[38]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[113]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[118]

Drug(s) Targeting Low-density lipoprotein receptor (LDL-R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Porfimer Sodium	DM7ZWNY	Non-small-cell lung cancer	2C25.Y	Approved	[38]

Drug(s) Targeting Immunoglobulin epsilon Fc receptor gamma (FCERG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omalizumab	DMETVFJ	Asthma	CA23	Approved	[119]
Benzylpenicilloyl Polylysine	DMQHM2D	Bacterial infection	1A00-1C4Z	Approved	[120]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[1]

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[121]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[122]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[123]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[124]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[125]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[126]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[127]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[128]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[128]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[128]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ADAM metallopeptidase 33 (ADAM33)	TTQICM2	ADA33_HUMAN	Inhibitor	[1]
Alpha-galactosidase A (GLA)	TTIS03D	AGAL_HUMAN	Inhibitor	[1]
Antithrombin-III (ATIII)	TT4QPUL	ANT3_HUMAN	Inhibitor	[1]
Beta-2-glycoprotein 1 (APOH)	TT2OUI9	APOH_HUMAN	Inhibitor	[1]
Cathepsin D (CTSD)	TTPT2QI	CATD_HUMAN	Inhibitor	[1]
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Inhibitor	[1]
Deoxyribonuclease I (DNASE1)	TTYWGOJ	DNAS1_HUMAN	Inhibitor	[1]
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Inhibitor	[1]
Glycoprotein hormones alpha (CGA)	TTFC29G	GLHA_HUMAN	Inhibitor	[1]
Heparin cofactor II (SERPIND1)	TT8XSKJ	HEP2_HUMAN	Inhibitor	[1]
Immunoglobulin epsilon Fc receptor gamma (FCERG)	TTDGEC0	FCERG_HUMAN	Inhibitor	[1]
Influenza Hemagglutinin (Influ HA)	TTF4CAM	HEMA_I34A1	Inhibitor	[1]
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[1]
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Inhibitor	[1]
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Inhibitor	[1]
Lactase-phlorizin hydrolase (LCT)	TTA0OSE	LPH_HUMAN	Inhibitor	[1]
Lactotransferrin (LTF)	TTSZDQU	TRFL_HUMAN	Inhibitor	[1]
Liver carboxylesterase (CES1)	TTMF541	EST1_HUMAN	Inhibitor	[1]
Low-density lipoprotein receptor (LDL-R)	TTH0DUS	LDLR_HUMAN	Inhibitor	[1]
Membrane-associated lectin type-C (CD209)	TTBXIM9	CD209_HUMAN	Inhibitor	[1]
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[1]
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[1]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[1]
Reticulon-4 receptor (RTN4R)	TTVRZUO	RTN4R_HUMAN	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]
T-cell surface antigen CD2 (CD2)	TTJDUNO	CD2_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
• [3] Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49.
• [4] Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.
• [5] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [6] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [7] Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478.
• [8] Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
• [9] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [11] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [12] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [13] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [14] Clinical pipeline report, company report or official report of MacroGenics
• [15] Clinical pipeline report, company report or official report of Xencor
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [18] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [21] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [22] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
• [23] Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
• [24] Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
• [25] AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
• [26] Clinical pipeline report, company report or official report of Avrobio.
• [27] AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
• [28] Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
• [29] ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
• [30] 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
• [31] New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81.
• [32] Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8.
• [33] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [34] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [35] Clinical pipeline report, company report or official report of Takeda (2009).
• [36] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [37] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [38] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [39] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [40] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [41] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [42] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [43] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [44] Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
• [45] Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
• [46] Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
• [47] Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
• [48] Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
• [49] Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
• [50] Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
• [51] A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
• [52] Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
• [53] Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
• [54] Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
• [55] US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
• [56] CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
• [57] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [58] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [59] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [60] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [61] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [62] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [63] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [64] Clinical pipeline report, company report or official report of Amgen (2009).
• [65] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [66] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [67] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [68] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [69] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [70] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [71] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [72] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [73] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [74] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [75] Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
• [76] Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
• [77] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [78] Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
• [79] alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
• [80] Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
• [81] Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.
• [82] Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
• [83] The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
• [84] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [85] Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
• [86] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
• [87] Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
• [88] Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
• [89] Company report (kyowa-kirin)
• [90] Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
• [91] Clinical pipeline report, company report or official report of Momentapharma.
• [92] Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.
• [93] Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
• [94] A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
• [95] Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
• [96] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
• [97] New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
• [98] Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
• [99] RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
• [100] Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
• [101] ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
• [102] Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
• [103] Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
• [104] Clinical pipeline report, company report or official report of Roche.
• [105] Clinical pipeline report, company report or official report of Visterra.
• [106] An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
• [107] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [108] A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
• [109] Clinical pipeline report, company report or official report of Vir Biotechnology.
• [110] Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
• [111] Company report (PaxVax)
• [112] Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.
• [113] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [114] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [115] IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
• [116] Clinical pipeline report, company report or official report of Ablynx.
• [117] The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
• [118] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [119] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [120] Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.
• [121] Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
• [122] Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
• [123] Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
• [124] Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
• [125] Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
• [126] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
• [127] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [128] A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.